A short AI chat tells a different story of brilacidin’s so called adverse effects
Blood pressure / hypertensive events
In a Phase 2 trial comparing brilacidin to daptomycin (for skin infections), the most common adverse events included numbness/tingling. In that study, “elevated systolic blood pressure” was reported in 1.9% of the low-dose, 3.7% of the medium dose, and 5.6% of the high dose brilacidin groups. These elevations were transient and resolved in less than 24 hours.
Medscape
In the same report, the investigators noted possible “methodological errors” because of geographic clustering of the BP-elevation events, which raises uncertainty about whether the elevations were drug-related.
Medscape
Another source (PolyMedix presentation) states that, in 160 patients treated with brilacidin, rare cases of transient systolic blood pressure elevations occurred in 6/160 (3.8?%).
GlobeNewswire
No data in these sources suggest consistent, severe, or sustained hypertensive spikes as a common effect.
At this point does it even matter, surely this ceo has proved themselves incompetent. So for now the fight is not for share holder value but to avoid paying back rents. It's over.
Market Data 
Markets 
AI
